PALI vs PHGE

Palisade Bio, Inc. vs BiomX Inc. — Valuation Comparison 2026

PALI

Biological Products, (No Diagnostic Substances)
Palisade Bio, Inc.
Quality
4.0
out of 10
Value Trap
27
LOW
Price
$2.12
Last close
Models
7/13
Active
VS

PHGE

Biological Products, (No Diagnostic Substances)
BiomX Inc.
Quality
3.3
out of 10
Value Trap
44
WARN
Price
$1.26
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType PALI Fair ValuePALI Upside PHGE Fair ValuePHGE Upside
Bayesian DCF Intrinsic $0.91 -56.9% $0.48 -56.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.86 -59.3% $2.33 +85.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PALI vs PHGE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PALI vs PHGE — Which Stock Is More Undervalued?

PALI scores higher with a 4.0/10 quality rating vs PHGE's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Palisade Bio, Inc. (PALI) and BiomX Inc. (PHGE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PALI currently trades at $2.12 with a QOC of 4.0/10, while PHGE trades at $1.26 with a QOC of 3.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).